This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
5 ETFs to Play in July
by Sanghamitra Saha
Investors may tap these five ETFs for gains as President Trump aims the first shot in the trade war.
Want to Tap Merger Mania? Play Top-Ranked Health Care ETFs
by Sanghamitra Saha
What is driving Healthcare merger-mania and how to tap it with ETFs.
5 ETF Ways to Trade 6-Year High U.S. Inflation
by Sanghamitra Saha
Why these ETF areas can gain in an inflationary environment.
Play the Best Sector of Summer With These ETFs & Stocks
by Sanghamitra Saha
Health care is apparently one of the best-performing sectors of summer. So, track these ETFs and stocks.
Should You Invest in the PowerShares S&P SmallCap Health Care Portfolio (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Don't Sell in May and Go Away: Follow These ETF Strategies
by Sweta Killa
Investors could follow some ideas that could lead to a winning portfolio during this soft six-month period.
Healthcare ETFs in Focus After Johnson & Johnson Q1 Earnings
by Zacks Equity Research
Johnson & Johnson reports Q1 results with both revenues and EPS beating estimates.
Healthy Q1 Earnings at UnitedHealth: ETFs to Watch
by Sanghamitra Saha
Solid earnings at UnitedHealth should boost these ETFs.
Should You Invest in the PowerShares S&P SmallCap Health Care Portfolio (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Cigna to Buy Express Scripts: Healthcare ETFs in Focus
by Sweta Killa
Waves of mergers and acquisitions have been heating up the healthcare space.
Healthcare ETFs in Focus Post JNJ Q4 Results
by Sweta Killa
Investors should closely watch the movement of the JNJ following Q4 results and keep a close eye on ETFs having double-digit allocation to this diversified drug maker.
Ride on UnitedHealth's Solid Q4 Results With These ETFs
by Sweta Killa
UnitedHealth breezed past the Zacks Consensus Estimate on both the top and the bottom lines as well as raised its full-year outlook, sending shares of UNH to record highs.
Tax Bill: What ETF Investors Need to Know
by Sanghamitra Saha
The tax bill has finally been passed by both the House and the Senate. Here is what you need to know.
The Zacks Analyst Blog Highlights: U.S. Tax Reform Fund, First Trust Large Cap Growth AlphaDEX, iShares U.S. Dividend and Buyback, SPDR S&P Homebuilders
by Zacks Equity Research
The Zacks Analyst Blog Highlights: U.S. Tax Reform Fund, First Trust Large Cap Growth AlphaDEX, iShares U.S. Dividend and Buyback, SPDR S&P Homebuilders
House Passes Tax Bill: Likely ETF Winners & Losers
by Sanghamitra Saha
The House passes the tax bill. These ETFs may emerge winners and losers in the coming days.
Winners & Loser of Trump's Tax Reform
by Sanghamitra Saha
Republicans propose tax reform bill. These ETFs could benefit or lose if the bill is enacted.
Healthcare ETFs Head to Head: XLV vs. VHT
by Zacks Equity Research
Head to head comparison of two Healthcare ETFs, XLV and VHT.
Healthcare ETFs in Focus on Johnson & Johnson Q3 Earnings
by Zacks Equity Research
Johnson & Johnson reports Q3 results with both revenues and EPS beating estimates.
Ride On UnitedHealth Q3 Strength with These ETFs
by Sanghamitra Saha
Play upbeat earnings of UnitedHealth Group with these ETFs.
ETFs to Buy After Weak Jobs Report
by Sanghamitra Saha
Hurricanes hit U.S. September job data hard. But these ETFs still hold promise.
4 Big ETF Launches of Third-Quarter 2017
by Sweta Killa
We highlight four ETFs that have been able to pull in over $120 million in AUM and have huge potential to dominate the market in the coming months.
Stock Investing Strategy When at All Time Highs
by Jeremy Mullin
If you want to participate in the next round of new highs, then NOW is the time to develop a game plan. Jeremy Mullin will show you how.
Volatility Spikes on Geopolitics: 4 ETF Tactics to Shield
by Sweta Killa
We have highlighted certain ETF techniques that could lead to a winning portfolio amid the heightened geopolitical tension.
J&J Brightens Outlook: Healthcare ETFs in Focus
by Sweta Killa
Johnson & Johnson continued its long streak of earnings beat and offered an upbeat outlook for the full year. However, it lagged our revenue estimate.
How to Build a Winning ETF Portfolio for Second-Half 2017
by Sweta Killa
If we go by history, stocks have generated positive returns in the second half of the year over the past two decades.